Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
The cold, hard fact of the matter is this: Without a solution like GLP-1 drugs, the obesity rate will likely continue climbing
Semaglutide From$14.99 CAS 910463-68-2 MW 4113.58 Semaglutide from the Nexus GLP-1 & Metabolic catalog, supplied for controlled in-vitro research workflows
The mitigation is well-established and unglamorous: lift weights, eat enough protein
Reduction in major cardiovascular events (SELECT trial, semaglutide) Reduced risk of progressing from prediabetes to type 2 diabetes (Tirzepatide, 3yr trial) Weight reduction significantly improves sleep apnea severity confirmed in multiple GLP-1 trials Emerging ADA 2026 data on GLP-1 anti-inflammatory effects and osteoarthritis improvement Improved basal metabolic rate and energy utilisation, especially with tirzepatides GIP pathway We believe cost transparency is part of quality care
US$ 24.34
US$ 22.41
US$ 23.78
US$ 28.67
US$ 23.49
US$ 24.41
US$ 22.28
US$ 28.58
